cnbc.comEli Lilly's obesity pill remains a viable rival to Novo's oral Wegovy despite data that underwhelmed investorsabout 2 months ago
benzinga.comViking Obesity Pill Faces Steep Climb Against Lilly's Tirzepatide, Analyst Calls Downtrend Reaction 'Extreme'2 months ago
cnbc.comStocks making the biggest moves midday: Home Depot, Intel, Viking Therapeutics, Nvidia and more2 months ago
CashuViking Therapeutics Stock Sentiment Shifts Amid High Short Interest and Clinical Developmentsabout 1 month ago
CashuViking Therapeutics Faces Market Skepticism Amid High Short Interest and Clinical Development Challengesabout 1 month ago
CashuViking Therapeutics: Key Clinical Trials and Strategic Partnerships Shape Future Prospectsabout 1 month ago